Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.83+0.30 (+1.05%)
Close on Nov 13, 2026Market cap $2.26BP/E –Yield –
Celldex Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Celldex Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -195608.9%. For fiscal 2025 it was -16748.0%, against -2248.8% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -16748.0% | −14499.3 |
| FY2024 | Dec 31, 2024 | -2248.8% | −194.0 |
| FY2023 | Dec 31, 2023 | -2054.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -334104.5% | −326364.1 |
| Q1 FY2026 | Mar 31, 2026 | -524566.7% | −520558.8 |
| Q4 FY2025 | Dec 31, 2025 | -67204.1% | −65884.1 |
| Q2 FY2025 | Jun 30, 2025 | -7753.4% | −6318.6 |
| Q1 FY2025 | Mar 31, 2025 | -7740.4% | +13290.3 |
| Q4 FY2024 | Dec 31, 2024 | -4007.8% | – |
| Q3 FY2024 | Sep 30, 2024 | -1320.0% | – |
| Q2 FY2024 | Jun 30, 2024 | -1434.8% | – |
| Q1 FY2024 | Mar 31, 2024 | -21030.8% | – |
See a number that looks wrong?